Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

Bernardez, Beatriz; Bruna, Jordi; Arriola, Edurne; De Castro, Javier; Garcia Campelo, Rosario; Bernabé, Reyes; FELIP, ENRIQUETA

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Bernardez, Beatriz
dc.contributor.author	Bruna, Jordi
dc.contributor.author	Arriola, Edurne
dc.contributor.author	De Castro, Javier
dc.contributor.author	Garcia Campelo, Rosario
dc.contributor.author	Bernabé, Reyes
dc.contributor.author	FELIP, ENRIQUETA
dc.date.accessioned	2025-02-12T13:37:02Z
dc.date.available	2025-02-12T13:37:02Z
dc.date.issued	2024-08
dc.identifier.citation	Arriola E, de Castro J, García-Campelo R, Bernárdez B, Bernabé R, Bruna J, et al. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. Clin Drug Investig. 2024 Aug;44(8):553–76.
dc.identifier.issn	1179-1918
dc.identifier.uri	https://hdl.handle.net/11351/12591
dc.description	Consens; Esdeveniments adversos; Càncer de pulmó de cèl·lules no petites
dc.description.sponsorship	This project was developed with funding from Pfizer.
dc.language.iso	eng
dc.publisher	Adis
dc.relation.ispartofseries	Clinical Drug Investigation;44(8)
dc.rights	Attribution-NonCommercial 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc/4.0/
dc.source	Scientia
dc.subject	Decisió de grup
dc.subject	Proteïnes quinases - Inhibidors - Ús terapèutic - Efectes secundaris
dc.subject	Pulmons - Càncer - Tractament
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	/drug therapy
dc.subject.mesh	Protein Kinase Inhibitors
dc.subject.mesh	/therapeutic use
dc.subject.mesh	Anaplastic Lymphoma Kinase
dc.subject.mesh	/antagonists & inhibitors
dc.title	Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1007/s40261-024-01379-7
dc.subject.decs	carcinoma de pulmón de células no pequeñas
dc.subject.decs	/farmacoterapia
dc.subject.decs	inhibidores de proteínas cinasas
dc.subject.decs	/uso terapéutico
dc.subject.decs	cinasa del linfoma anaplásico
dc.subject.decs	/antagonistas & inhibidores
dc.relation.publishversion	https://doi.org/10.1007/s40261-024-01379-7
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Arriola E] Medical Oncology Department, Hospital del Mar, Center for Biomedical Network Research on Cancer (CIBERONC), Barcelona, Spain. [de Castro J] Medical Oncology Department, La Paz University Hospital, Hospital La Paz Health Research Institute (IdiPAZ), Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain. [García Campelo R] Medical Oncology Department, A Coruña University Hospital, Biomedical Research Institute of A Coruña (INIBIC), A Coruña, Spain. [Bernárdez B] Oncological Pharmacy Unit, Santiago de Compostela University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, A Coruña, Spain. [Bernabé R] Medical Oncology Department, Virgen del Rocío University Hospital, Biomedicine Institute of Sevilla (IBIS), University of Sevilla, Sevilla, Spain. [Bruna J] Neuro-Oncology Unit, Bellvitge University Hospital, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid	39085682
dc.identifier.wos	001281860100001
dc.rights.accessrights	info:eu-repo/semantics/openAccess